Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cizutamig in Thyroid Eye Disease
NCT07597200Phase 1Recruiting
- Sponsor
- Candid Therapeutics
- Start
- May 2026
- Primary completion
- May 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cizutamig in thyroid eye disease (TED), sponsored by Candid Therapeutics. Primary endpoints: Incidence and severity of treatment-emergent adverse events at 12 months, Changes from baseline in vital signs at 12 months and 2 more. Started May 2026; status: recruiting.
02
Drugs
cizutamig
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT07597200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07597200.